IQVIA's Q1 2025: Navigating Contradictory Signals on Growth, Partnerships, and Pricing
Earnings DecryptTuesday, May 6, 2025 8:22 pm ET

IQV Total Revenue YoY, Total Revenue
Revenue and Profit Growth:
- reported revenue of $3,829 million for Q1 2025, growing 2.5% on a reported basis and 3.5% at constant currency.
- First quarter adjusted EBITDA increased 2.4%, and adjusted diluted EPS rose 6.3% year-over-year to $2.70.
- The growth was driven by strong performance in the TAS segment and the exclusion of $40 million in COVID-related revenue from the prior year.
TAS Segment Growth:
- Technology & Analytics Solutions (TAS) revenue was $1,546 million, up 6.4% reported and 7.6% at constant currency.
- TAS growth was primarily driven by double-digit growth in real-world evidence and strong revenue contributions from new drug launches and commercialization efforts.
R&D Solutions and Bookings:
- revenue was $2,102 million, up 0.3% reported and 1.1% at constant currency.
- The R&D bookings were affected by delayed decision-making by customers and lower EBP funding, leading to higher-than-normal EBP awards without secured funding.
- The challenges were linked to uncertainty surrounding new U.S. government initiatives and delayed decision-making due to macroeconomic factors.
Impact of Macroeconomic Uncertainty:
- The company experienced delayed RFP-to-award decision-making, with an approximate 10% increase year-over-year and sequentially.
- The R&D backlog reached $31.5 billion, showing a 4.8% year-over-year growth.
- The macroeconomic uncertainty, particularly the pronouncements by the new U.S. administration, led to cautious customer decision-making and a deterioration in EBP funding.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet